Ipratropium (Br)
Overview
Ipratropium (Br) is a quaternary derivative of atropine and a cholinergic blocking agent. It was the first muscarinic receptor blocking agent to acheive wide therapetic use in a pressurized aerosol. Ipratropium (Br) is prepared by chemical synthesis and the racemate is used clinically. It causes dialatation of bronchiol and is used to treat asthma and obstructive pulmonary disease. Ipratropium (Br) is available for inhalational administration.
Categories
- 25 Drugs acting on the respiratory tract
- 25.1 Anti-asthmatic drugs
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Back to top
Back to top
Back to top
Side Effects
Back to top
Dosage
Carbazochrome's dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 20 to 40 mcg | 30 (30) | 8 hourly | Inhalation | Frequency may be increased upto 4 times/day if needed. |
Paedriatic Dosage (20kg)
|
| 125 to 0 ug | 62 (62.5) | 6 hourly | | To total dose of 1mg for asthma). |
| 20 ug | 20 (20) | 8 hourly | Inhalation | As Required. Reversible airways obstruction. |
Neonatal Dosage (3kg)
|
| 12.5 ug/kg | 12 (12.5) | 8 hourly | Inhalation | Via nebulizer |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
No data regarding the pathological interferences produced by Ipratropium (Br) is available.
Back to top
Brands / Trade Names of
Carbazochrome
Back to top
Manufacturers of
Ipratropium (Br)
in Pakistan
Back to top
Previous Drug Generic - Next Drug Generic